Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05787418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Enrolling by Invitation → Completed Show 5 more changesShow less
    • Final enrollment: 918 participants (planned 1200)
    • Primary completion date changed from estimate of Dec 31, 2025 to Mar 27, 2024
    • Study completion date changed from estimate of Apr 1, 2026 to Apr 17, 2024
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 1 of 10 entries
  2. Primary completion date: Dec 31, 2023 to Dec 31, 2025
    • Trial status: Recruiting to Enrolling by Invitation
    • Study completion date: Jun 1, 2024 to Apr 1, 2026
    • Site details revised at 2 of 2 sites
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 28, 2023 to Mar 31, 2023
    • Site details revised at 2 of 2 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Huahui Health
9 trials monitored
See 1 trial at risk
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
Trial Details
NCT Number NCT05787418
Lead Sponsor Huahui Health
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19
Enrollment 918 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov